Compare Chipotle Mexican Grill, Inc. (CMG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.32 (market cap $40.67B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2× Chipotle Mexican Grill, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| CMG | REGN | |
|---|---|---|
Market Cap | $40.67B | $83.19B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $812.27 |
52-Week Low | $28.17 | $555.51 |
Enterprise Value | $45.42B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.81, down 2.67% amid food safety concerns. The stock shows bearish technical signals with strong analyst support (70% buy ratings) and a $42.17 consensus target. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $0.33 exceeding estimates. Revenue growth remains steady, climbing from $8.6B in 2022 to $11.9B in 2025, though net income margin compressed to 11.42% in 2026 from 13.55% in 2024.
Despite strong fundamentals and analyst optimism, CMG faces near-term headwinds from salmonella outbreaks and fraud investigations. The stock's premium valuation (P/E 29.76) requires sustained execution amid operational challenges. Long-term growth trajectory remains intact, but current sentiment is cautious due to food safety issues and legal scrutiny.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
